Q-Line Biotech Ltd.
QLINESME
Ask IPO
Overview
Q-Line Biotech Limited develops, manufactures and markets in-vitro diagnostic reagents, kits, point-of-care devices, consumables and diagnostic equipment for hospitals, laboratories, medical colleges and diagnostic service providers. Q-Line Biotech Limited has operated in the Indian IVD market since 2013, with core segments spanning clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and rapid/POC products. The company combines indigenous manufacturing, technical collaborations, in-house R&D, multiple manufacturing facilities in Lucknow and Delhi, and a distributor-led B2B network with strong concentration in northern India, particularly Uttar Pradesh.
Opening Date
May 21, 2026
Closing Date
May 25, 2026
Listing Date
May 29, 2026
IPO Type
SME
IPO Status
Closed
Issue Size
214.48 Cr
Fresh Issue
214.48 Cr
Offer for Sale
0 Cr
Price Band
₹326 - ₹343
Lot Size
400
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
The main objectives of the issue are to strengthen Q-Line Biotech Limited's balance sheet and support business expansion.
- •
Meeting working capital requirements of the company, primarily to fund higher inventory, trade receivables, supplier advances, security deposits and day-to-day operational needs arising from growth in the reagents, instruments and diagnostics business.
- •
Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by the company from banks and financial institutions, in order to reduce indebtedness, lower debt servicing costs and improve the debt-equity position.
- •
Funding general corporate purposes, which may include supporting business development, operational strengthening, strategic initiatives and other corporate requirements, subject to applicable regulatory limits.
- •
Enhancing corporate image, improving brand visibility and creating liquidity for shareholders through listing of the equity shares on the SME platform of NSE.
Key Performance Indicator
P/E Ratio
—
EPS
—
ROE
16.88%
ROCE
13.32%
RONW
16.88%
Debt to Equity Ratio
—
PAT Margin
16.65%
EBITDA Margin
27.64%
P/B
—
SWOT Analysis
Strengths
- •
Established presence in the Indian IVD industry with a diversified portfolio across reagents, instruments, consumables and service offerings.
- •
Research-driven manufacturing platform supported by in-house R&D, technical collaborations and multiple manufacturing facilities in Lucknow and Delhi.
- •
Wide distributor-led sales network with presence across several Indian states and long-standing relationships with repeat customers.
- •
Strong operating scale-up reflected in rising revenue, expanding assets and healthy profitability metrics over recent financial years.
Weaknesses
- •
Business has significant geographic concentration, with a large share of revenue coming from Uttar Pradesh and the northern region.
- •
Customer concentration is high, with top customers contributing a substantial portion of revenue from operations.
- •
Working capital intensity is elevated because of higher inventory holding periods and extended credit terms to customers.
- •
Business depends materially on imported raw materials and equipment components, exposing operations to supply and currency risks.
Opportunities
- •
Growing Indian IVD market driven by healthcare awareness, chronic disease burden, preventive diagnostics and improving healthcare access.
- •
Expansion of Make in India manufacturing can increase localization, reduce import dependence and improve margins across diagnostics products.
- •
New product development in analysers, reagents and point-of-care devices can deepen wallet share with existing laboratories and hospitals.
- •
Potential to grow exports and expand beyond the current domestic stronghold into African, Middle Eastern and other international markets.
Threats
- •
Regulatory changes in medical devices, healthcare and quality compliance may increase costs or delay approvals for products.
- •
Global supply-chain disruptions, freight inflation and geopolitical tensions can affect availability and pricing of imported inputs.
- •
Intense competition from established IVD and diagnostics players can pressure pricing, margins and market share.
- •
Economic slowdown, hospital procurement delays or lower diagnostic spending may adversely affect demand and receivable cycles.
Subscription Rate
Frequently Asked Questions about Q-Line Biotech Ltd.
Q-Line Biotech Limited develops, manufactures and markets in-vitro diagnostic reagents, kits, point-of-care devices, consumables and diagnostic equipment for hospitals, laboratories, medical colleges and diagnostic service providers. Q-Line Biotech Limited has operated in the Indian IVD market since 2013, with core segments spanning clinical chemistry, haematology, immunodiagnostics, molecular diagnostics and rapid/POC products. The company combines indigenous manufacturing, technical collaborations, in-house R&D, multiple manufacturing facilities in Lucknow and Delhi, and a distributor-led B2B network with strong concentration in northern India, particularly Uttar Pradesh.
The Q-Line Biotech Ltd. IPO is scheduled to open for subscription on May 21, 2026 and close on May 25, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Q-Line Biotech Ltd. IPO is ₹326 to ₹343. Investors can place bids within this range once the issue opens.
The minimum lot size for the Q-Line Biotech Ltd. IPO is 400 shares. The minimum investment amount ₹1,37,200.
The total issue size of the Q-Line Biotech Ltd. IPO is approximately ₹214.48. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Q-Line Biotech Ltd. IPO has been subscribed 9.87 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Q-Line Biotech Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Q-Line Biotech Ltd. are expected to list on stock exchanges on May 29, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Q-Line Biotech Ltd. IPO are proposed to be used for The main objectives of the issue are to strengthen Q-Line Biotech Limited's balance sheet and support business expansion., Meeting working capital requirements of the company, primarily to fund higher inventory, trade receivables, supplier advances, security deposits and day-to-day operational needs arising from growth in the reagents, instruments and diagnostics business., Repayment or prepayment, in full or in part, of certain outstanding borrowings availed by the company from banks and financial institutions, in order to reduce indebtedness, lower debt servicing costs and improve the debt-equity position., Funding general corporate purposes, which may include supporting business development, operational strengthening, strategic initiatives and other corporate requirements, subject to applicable regulatory limits., Enhancing corporate image, improving brand visibility and creating liquidity for shareholders through listing of the equity shares on the SME platform of NSE.
Before applying for the Q-Line Biotech Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
